IN2012MN02896A - - Google Patents

Download PDF

Info

Publication number
IN2012MN02896A
IN2012MN02896A IN2896MUN2012A IN2012MN02896A IN 2012MN02896 A IN2012MN02896 A IN 2012MN02896A IN 2896MUN2012 A IN2896MUN2012 A IN 2896MUN2012A IN 2012MN02896 A IN2012MN02896 A IN 2012MN02896A
Authority
IN
India
Prior art keywords
hydroxychloroquine
hcv
disclosed
hepatitis
virus
Prior art date
Application number
Other languages
English (en)
Inventor
Philippe Halfon
Original Assignee
Panmed Ltd
Genoscience Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panmed Ltd, Genoscience Pharma Sas filed Critical Panmed Ltd
Publication of IN2012MN02896A publication Critical patent/IN2012MN02896A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2896MUN2012 2010-06-24 2011-06-23 IN2012MN02896A (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35801410P 2010-06-24 2010-06-24
PCT/IB2011/052762 WO2011161644A1 (en) 2010-06-24 2011-06-23 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent

Publications (1)

Publication Number Publication Date
IN2012MN02896A true IN2012MN02896A (cs) 2015-06-12

Family

ID=44630083

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2896MUN2012 IN2012MN02896A (cs) 2010-06-24 2011-06-23

Country Status (10)

Country Link
US (2) US8987302B2 (cs)
EP (1) EP2585065A1 (cs)
JP (1) JP2013529627A (cs)
CN (1) CN103096891A (cs)
AU (1) AU2011268498A1 (cs)
BR (1) BR112012033022A2 (cs)
CA (1) CA2803093A1 (cs)
IN (1) IN2012MN02896A (cs)
MX (1) MX2013000242A (cs)
WO (1) WO2011161644A1 (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012MN02896A (cs) 2010-06-24 2015-06-12 Panmed Ltd
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
CN103145811B (zh) * 2013-03-15 2014-05-07 深圳翰宇药业股份有限公司 一种合成阿拉泊韦的方法
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
MX2022012938A (es) * 2020-04-20 2023-02-09 Glanis Pharmaceuticals Inc Sistema de entrega oral que comprende hidroxicloroquina y/o cloroquina.
EP4142773A4 (en) * 2020-04-29 2023-11-01 The Regents Of The University Of Michigan INHIBITION OF VIRAL ENTRY OF SARS-COV-2 BY ADMINISTRATION OF LACTOFERRIN AND ITS USES
JP7477152B2 (ja) 2020-05-12 2024-05-01 国立大学法人 宮崎大学 Ｈｔｌｖ－１関連疾患の発症予防、進展抑制または治療のための剤
WO2022161355A1 (en) 2021-01-26 2022-08-04 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
CN114796126B (zh) * 2022-04-02 2023-04-18 复旦大学附属中山医院青浦分院(上海市青浦区中心医院) 关节腔注射用硫酸羟氯喹缓释微球及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5314894A (en) 1992-09-15 1994-05-24 Sterling Winthrop Inc. (S)-(+)-hydroxychloroquine
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6849254B1 (en) 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
EP1282632A1 (en) 2000-04-20 2003-02-12 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
WO2005077042A2 (en) 2004-02-09 2005-08-25 Human Genome Sciences, Inc. Albumin fusion proteins
ITBO20020416A1 (it) * 2002-06-28 2003-12-29 Valpharma Sa Uso della clorochina, idrossi-clorochina e derivati 4 amino-chinolinici per l'ottenimento di un farmaco per la terapia anti retrovirale atti
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP2189159A1 (en) 2003-02-21 2010-05-26 Jarrow Formulas, Inc. Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
WO2005049065A2 (en) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
KR20070036175A (ko) 2004-07-14 2007-04-02 노파르티스 아게 Ｃ형 간염(ｈｃｖ)의 치료를 위한 시클로스포린과ｐｅｇ화된 인터페론의 조합 제제의 용도
WO2006109196A2 (en) 2005-02-04 2006-10-19 Tripep Ab Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics
JP4705164B2 (ja) 2005-05-02 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
MX2008001588A (es) 2005-08-01 2008-02-19 Merck & Co Inc Inhibidores de proteasa ns3 del vhc.
WO2010101649A2 (en) * 2009-03-05 2010-09-10 Pablo Gastaminza Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
PE20121526A1 (es) 2010-01-27 2012-12-06 Pharma Ltd Ab Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c
IN2012MN02896A (cs) 2010-06-24 2015-06-12 Panmed Ltd
WO2012061248A2 (en) 2010-11-01 2012-05-10 Rfs Pharma, Llc Novel specific hcv ns3 protease inhibitors
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus

Also Published As

Publication number Publication date
US8987302B2 (en) 2015-03-24
EP2585065A1 (en) 2013-05-01
WO2011161644A1 (en) 2011-12-29
JP2013529627A (ja) 2013-07-22
CA2803093A1 (en) 2011-12-29
US8575195B2 (en) 2013-11-05
BR112012033022A2 (pt) 2016-12-20
US20130121965A1 (en) 2013-05-16
CN103096891A (zh) 2013-05-08
US20130202556A1 (en) 2013-08-08
AU2011268498A1 (en) 2013-01-31
MX2013000242A (es) 2014-04-14

Similar Documents

Publication Publication Date Title
IN2012MN02896A (cs)
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
PH12014502847A1 (en) Combination treatment (eg with abt-072-333) of daas for use in treating hcv
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
NZ702744A (en) D-amino acid compounds for liver disease
MY160130A (en) Hepatitis c virus inhibitors
EA033257B1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
PH12014501133A1 (en) Compositions and methods for treating hepatitis c virus
IN2014MN01547A (cs)
MX2010008148A (es) Métodos de tratamiento de infecciones virales.
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
WO2010085091A3 (en) Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components
TN2011000204A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
MX2020011107A (es) Regimen de glicosidasa para el tratamiento de enfermedades infecciosas.
WO2014116772A3 (en) Squaric derivatives for the treatment of hepatitis c
MX2014014878A (es) Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv).
WO2012006550A3 (en) Methods and compositions for treatment of lipogenic virus related conditions
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
WO2012040164A3 (en) Tlr5 ligands, therapeutic methods, and compositions related thereto
PH12012501303A1 (en) Compositions and methods for treating hepatitis b virus infection
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
ES2572355A2 (es) Combinacion de aad para uso en el tratamiento del vhc